FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4323556839> ?p ?o ?g. }

• W4323556839 endingPage "e14502" @default.
• W4323556839 startingPage "e14502" @default.
• W4323556839 abstract "Multidrug-resistant tuberculosis (MDR-TB) is one of the world's most devastating contagious diseases and is caused by the MDR-Mycobacterium tuberculosis (MDR-Mtb) bacteria. It is therefore essential to identify novel anti-TB drug candidates and target proteins to treat MDR-TB. Here, in vitro and in silico studies were used to investigate the anti-TB potential of two newly sourced actinomycins, actinomycin-X2 (act-X2) and actinomycin-D (act-D), from the Streptomyces smyrnaeus strain UKAQ_23 (isolated from the Jubail industrial city of Saudi Arabia).The anti-TB activity of the isolated actinomycins was assessed in vitro using the Mtb H37Ra, Mycobacterium bovis (BCG), and Mtb H37Rv bacterial strains, using the Microplate Alamar Blue Assay (MABA) method. In silico molecular docking studies were conducted using sixteen anti-TB drug target proteins using the AutoDock Vina 1.1.2 tool. The molecular dynamics (MD) simulations for both actinomycins were then performed with the most suitable target proteins, using the GROningen MAchine For Chemical Simulations (GROMACS) simulation software (GROMACS 2020.4), with the Chemistry at HARvard Macromolecular Mechanics 36m (CHARMM36m) forcefield for proteins and the CHARMM General Force Field (CGenFF) for ligands.In vitro results for the Mtb H37Ra, BCG, and Mtb H37Rv strains showed that act-X2 had minimum inhibitory concentration (MIC) values of 1.56 ± 0.0, 1.56 ± 0.0, and 2.64 ± 0.07 µg/mL and act-D had MIC values of 1.56 ± 0.0, 1.56 ± 0.0, and 1.80 ± 0.24 µg/mL respectively. The in silico molecular docking results showed that protein kinase PknB was the preferred target for both actinomycins, while KasA and pantothenate synthetase were the least preferred targets for act-X2and act-D respectively. The molecular dynamics (MD) results demonstrated that act-X2 and act-D remained stable inside the binding region of PknB throughout the simulation period. The MM/GBSA (Molecular Mechanics/Generalized Born Surface Area) binding energy calculations showed that act-X2 was more potent than act-D.In conclusion, our results suggest that both actinomycins X2 and D are highly potent anti-TB drug candidates. We show that act-X2is better able to antagonistically interact with the protein kinase PknB target than act-D, and thus has more potential as a new anti-TB drug candidate." @default.
• W4323556839 created "2023-03-09" @default.
• W4323556839 creator A5034900615 @default.
• W4323556839 creator A5040515485 @default.
• W4323556839 creator A5043933281 @default.
• W4323556839 creator A5046108902 @default.
• W4323556839 creator A5046522347 @default.
• W4323556839 creator A5048984623 @default.
• W4323556839 creator A5071048665 @default.
• W4323556839 creator A5078032577 @default.
• W4323556839 creator A5079949999 @default.
• W4323556839 date "2023-03-08" @default.
• W4323556839 modified "2023-10-16" @default.
• W4323556839 title "<i>In vitro</i> and <i>in silico</i> evaluations of actinomycin X₂and actinomycin D as potent anti-tuberculosis agents" @default.
• W4323556839 cites W1031578623 @default.
• W4323556839 cites W166848320 @default.
• W4323556839 cites W1882627505 @default.
• W4323556839 cites W1968984443 @default.
• W4323556839 cites W1975216078 @default.
• W4323556839 cites W1996038152 @default.
• W4323556839 cites W1997882784 @default.
• W4323556839 cites W2017324943 @default.
• W4323556839 cites W2021520922 @default.
• W4323556839 cites W2033900149 @default.
• W4323556839 cites W2039119424 @default.
• W4323556839 cites W2044039386 @default.
• W4323556839 cites W2044124954 @default.
• W4323556839 cites W2052842894 @default.
• W4323556839 cites W2058558815 @default.
• W4323556839 cites W2058666755 @default.
• W4323556839 cites W2101022201 @default.
• W4323556839 cites W2126576359 @default.
• W4323556839 cites W2134967712 @default.
• W4323556839 cites W2160787060 @default.
• W4323556839 cites W2166129831 @default.
• W4323556839 cites W2168240189 @default.
• W4323556839 cites W2206954826 @default.
• W4323556839 cites W2413160750 @default.
• W4323556839 cites W2469207752 @default.
• W4323556839 cites W2555870966 @default.
• W4323556839 cites W2589083433 @default.
• W4323556839 cites W2624316269 @default.
• W4323556839 cites W2728191945 @default.
• W4323556839 cites W2738564789 @default.
• W4323556839 cites W2808023813 @default.
• W4323556839 cites W2810224209 @default.
• W4323556839 cites W2921939682 @default.
• W4323556839 cites W2974645908 @default.
• W4323556839 cites W3016853545 @default.
• W4323556839 cites W3104396439 @default.
• W4323556839 cites W3117765953 @default.
• W4323556839 cites W3122419829 @default.
• W4323556839 cites W3150613769 @default.
• W4323556839 cites W3156638471 @default.
• W4323556839 cites W3180153317 @default.
• W4323556839 cites W3184198514 @default.
• W4323556839 cites W3186753140 @default.
• W4323556839 cites W4205328602 @default.
• W4323556839 doi "https://doi.org/10.7717/peerj.14502" @default.
• W4323556839 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36935926" @default.
• W4323556839 hasPublicationYear "2023" @default.
• W4323556839 type Work @default.
• W4323556839 citedByCount "1" @default.
• W4323556839 countsByYear W43235568392023 @default.
• W4323556839 crossrefType "journal-article" @default.
• W4323556839 hasAuthorship W4323556839A5034900615 @default.
• W4323556839 hasAuthorship W4323556839A5040515485 @default.
• W4323556839 hasAuthorship W4323556839A5043933281 @default.
• W4323556839 hasAuthorship W4323556839A5046108902 @default.
• W4323556839 hasAuthorship W4323556839A5046522347 @default.
• W4323556839 hasAuthorship W4323556839A5048984623 @default.
• W4323556839 hasAuthorship W4323556839A5071048665 @default.
• W4323556839 hasAuthorship W4323556839A5078032577 @default.
• W4323556839 hasAuthorship W4323556839A5079949999 @default.
• W4323556839 hasBestOaLocation W43235568391 @default.
• W4323556839 hasConcept C104317684 @default.
• W4323556839 hasConcept C114851261 @default.
• W4323556839 hasConcept C133936738 @default.
• W4323556839 hasConcept C142724271 @default.
• W4323556839 hasConcept C185592680 @default.
• W4323556839 hasConcept C202751555 @default.
• W4323556839 hasConcept C2775905019 @default.
• W4323556839 hasConcept C2777752497 @default.
• W4323556839 hasConcept C2777975735 @default.
• W4323556839 hasConcept C2780152424 @default.
• W4323556839 hasConcept C2781069245 @default.
• W4323556839 hasConcept C41685203 @default.
• W4323556839 hasConcept C42972112 @default.
• W4323556839 hasConcept C55493867 @default.
• W4323556839 hasConcept C71924100 @default.
• W4323556839 hasConcept C86803240 @default.
• W4323556839 hasConcept C89423630 @default.
• W4323556839 hasConceptScore W4323556839C104317684 @default.
• W4323556839 hasConceptScore W4323556839C114851261 @default.
• W4323556839 hasConceptScore W4323556839C133936738 @default.
• W4323556839 hasConceptScore W4323556839C142724271 @default.
• W4323556839 hasConceptScore W4323556839C185592680 @default.
• W4323556839 hasConceptScore W4323556839C202751555 @default.

• next